Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania by unknown
Ostacher et al. International Journal of Bipolar Disorders  (2015) 3:11 
DOI 10.1186/s40345-015-0026-0RESEARCH Open AccessPatterns of response to aripiprazole, lithium,
haloperidol, and placebo across factor
scores of mania
Michael J Ostacher1,2*, Trisha Suppes1,2, Alan C Swann3, James M Eudicone4, Wally Landsberg5, Ross A Baker6
and Berit X Carlson7Abstract
Background: A previous factor analysis of Young Mania Rating Scale and Montgomery-Åsberg Depression Rating Scale
items identified composite factors of depression, mania, sleep disturbance, judgment/impulsivity, and irritability/hostility
as major components of psychiatric symptoms in acute mania or mixed episodes in a series of trials of antipsychotics.
However, it is unknown whether these factors predict treatment outcome.
Methods: Data from six double-blind, randomized, controlled clinical trials with aripiprazole in acute manic or mixed
episodes in adults with bipolar I disorder were pooled for this analysis and the previously identified factors were
examined for their value in predicting treatment outcome. Treatment efficacy was assessed for aripiprazole (n = 1,001),
haloperidol (n = 324), lithium (n = 155), and placebo (n = 694) at baseline, days 4, 7, and 10, and then weekly to study
end. Mean change in factor scores from baseline to week 3 was assessed by receiver operating characteristics curves
for percentage factor change at day 4 and week 1.
Results: Subjects receiving aripiprazole, haloperidol, and lithium significantly improved mania factor scores versus
placebo. Factors most predictive of endpoint efficacy for aripiprazole were judgment/impulsivity at day 4 and mania
at week 1. Optimal factor score improvement for outcome prediction was approximately 40% to 50%. Early efficacy
predicted treatment outcome across all factors; however, response at week 1 was a better predictor than response
at day 4.
Conclusions: This analysis confirms clinical benefits in early treatment/assessment for subjects with bipolar mania and
suggests that certain symptom factors in mixed or manic episodes may be most predictive of treatment response.
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Bipolar disorder has historically been described as discrete
episodes of depression and mania. However, the structure
of an episode is far more complex, and it has long been
recognized that depressive and manic symptoms often
exist simultaneously during periods of illness and can com-
bine to create so-called ‘mixed states’ (Kraepelin 1921).
Subsequent enquiries focused on mixed mania consisting
of depressive symptoms during manic episodes (Kotin and* Correspondence: ostacher@stanford.edu
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in any medium, provided the original work is pGoodwin 1972; McElroy et al. 1992) or defined mixed
states as a form of mania combining syndromal depres-
sion and mania (Swann et al. 2009). To date, there has
been little consensus over the structure and definition
of a mixed state, making a correct clinical diagnosis
increasingly difficult. There is increasing evidence that
depressive features may be a component across episodes
of bipolar disorder (APA 2013; Swann et al. 2013a),
leading to a new use of the concept of a ‘mixed-features
specifier’ in the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-V) (APA 2013) ra-
ther than the previous term of mixed episodes as de-
scribed in the DSM-IV, text revision (APA 2000). Its an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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a characteristic of manic episodes (mania is a characte-
ristic of depressive episodes) or whether ‘mixety’ is a com-
bination of independent depressive and manic states.
Better understanding of the clinical structure of manic
episodes in subjects with bipolar disorder may be useful in
understanding treatment response and determining dif-
ferences in efficacy based on symptom dimensions.
Several factor analyses exploring the symptomatic
structure of manic episodes have confirmed the hetero-
geneity of manic and mixed episodes (Azorin et al. 2008;
Bertschy et al. 2007; Cassidy et al. 1998; Dilsaver et al.
1999; Harvey et al. 2008; Lipkovich et al. 2008; Rossi
et al. 2001; Sato et al. 2002; Swann et al. 2001), which
has an impact not only on classification of bipolar dis-
order but also on the choice of treatment. Recent treat-
ment algorithms sought to distinguish between euphoric
(classical) mania, dysphoric mania and mixed states,
psychotic mania, and hypomania to better personalize
treatment (Grunze et al. 2009). Therefore, the symptom-
atic structure of bipolar disorder is of interest as it can
potentially be used to differentially predict response to
treatment and guide treatment choice.
One important aspect of treatment strategies for
mania is the need for early clinical prediction of re-
sponse to a particular treatment. Previous analyses
showed that early response to lithium or ziprasidone
predicted treatment outcome in acute manic and mixed
episodes (Ketter et al. 2010; Swann et al. 1986). However,
this topic has never been investigated using specific,
clinically observable symptoms of manic or mixed epi-
sodes. Therefore, using the factor structure developed pre-
viously (Swann et al. 2013b), the relationship between early
response and treatment outcome was investigated. The
analysis was based on a series of randomized clinical trials
that led to the approval of aripiprazole for acute manic and
mixed states by the Food and Drug Administration (FDA):
three double-blind, placebo-controlled, 3-week studies
(El Mallakh et al. 2010; Keck et al. 2003; Sachs et al.
2006b), a double-blind, haloperidol-controlled, 12-week
study (Vieta et al. 2005), and two active- and placebo-
controlled, double-blind, 12-week studies (Keck et al.
2009; Young et al. 2009). Previously, baseline data from
these combined studies was used to conduct a rotated fac-
tor analysis followed by a cluster analysis using all items
from the Young Mania Rating Scale (YMRS) and the
Montgomery-Åsberg Depression Rating Scale (MADRS)
(Swann et al. 2013b) and to identify the factor structure of
psychiatric symptoms of the subjects included in these
studies. Subjects were stratified by symptom state accor-
ding to the DSM-IV criteria. The analysis identified five fac-
tors, characterized (in order of variance accounted for) as
depression, mania, sleep disturbance, judgment/impulsivity,
and irritability/hostility (Swann et al. 2013b). All manicepisodes, whether mixed or non-mixed, shared the same
factor and cluster structure, differing only in factor scores.
Lithium and haloperidol were chosen as comparators in
the included studies because of their proven, evidenced-
based use in the treatment of mania. Traditionally, lithium
was the major treatment used to ameliorate symptoms of
mania by reducing excitatory neurotransmitters (dopamine
and glutamate) and is also known for preventing re-
currence of manic and depressive episodes (Geddes et al.
2010; Malhi et al. 2013) and reducing the risk of suicide
(Tondo and Baldessarini 2000; Cipriani et al. 2013). Halo-
peridol, a typical antipsychotic, is non-selective and binds
to a broad range of receptors, exerting efficacy mainly
through the antagonism of dopamine receptors. It is well
established as a treatment for acute mania (Cipriani et al.
2011). Aripiprazole is a second-generation atypical anti-
psychotic with a mechanism of action that differs from
other typical and atypical antipsychotics. Aripiprazole is a
high-affinity partial agonist of the dopamine D2/D3 recep-
tor, with partial agonist activity at the 5HT1A receptor
and antagonist activity at the 5HT2A receptor (Burris
et al. 2002; Stark et al. 2007, Tadori et al. 2008). Like
lithium, there is evidence that the use of aripiprazole is
effective in preventing manic episodes (Goodwin et al.
2011).
The objectives of the post hoc analysis presented here
are to use these previously determined factors to cha-
racterize the effects of aripiprazole, comparative treatment
(haloperidol and lithium), and placebo in the management
of bipolar I disorder and to assess the value of early effi-
cacy in predicting efficacy at endpoint (week 3).
Methods
Study design
This was a post hoc analysis of pooled data from six
double-blind, randomized, controlled clinical trials with
aripiprazole, which included 2,179 subjects (≥18 years)
diagnosed with bipolar I disorder, as defined by the
DSM-IV (APA 2000), who were experiencing an acute
manic or mixed episode (El Mallakh et al. 2010; Keck
et al. 2003; Keck et al. 2009; Sachs et al. 2006b; Vieta
et al. 2005; Young et al. 2009) (Table 1). The study
protocols, procedures, and consent statements were ap-
proved by the Institutional Review Boards (IRBs) of each
participating site. Details of the study designs, duration,
and treatments are given in Table 1. In all six studies,
efficacy assessments included the YMRS total score
(primary efficacy outcome) and the MADRS Total
score. Factor analysis using YMRS and MADRS line
items performed using the principal components
method with varimax rotation (Tabachnik and Fidell
2007) identified five factors with eigenvalues >1
(Table 2). These factors were depression (factor 1),
mania (factor 2), sleep disturbance (factor 3), judgment/
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Table 2 Factors of bipolar mania identified from
aripiprazole studies (Swann et al. 2013b)
Factors Scale Item
(Total % variance)





MADRS Inability to feel
MADRS Pessimistic thoughts
MADRS Suicidal thoughts
Factor 2: mania (12.0%) MADRS Concentration difficulties
YMRS Elevated mood




Factor 3: sleep disturbance (7.5%) MADRS Reduced sleep
YMRS Sleep
Factor 4: judgment/impulsivity (6.7%) YMRS Sexual interest
YMRS Appearance
YMRS Insight
Factor 5: irritability/hostility (5.8%) YMRS Irritability
YMRS Disruptive, aggressive
behavior
All items with factor loading ≥0.4 are shown.
MADRS, Montgomery-Åsberg Depression Rating Scale; YMRS, Young Mania
Rating Scale.
Ostacher et al. International Journal of Bipolar Disorders  (2015) 3:11 Page 4 of 9impulsivity (factor 4), and irritability/hostility (factor 5)
(Swann et al. 2013b).
Treatment efficacy
Treatment efficacy was assessed for each treatment
(aripiprazole, haloperidol, lithium, and placebo) at base-
line, days 4, 7, and 10, and then weekly throughout the
study period to reflect clinical decision points for potential
treatment change during an acute episode. In the
12-week, active-controlled trials, efficacy was also assessed
at day 2 (Table 1). The primary efficacy endpoint was
mean change from baseline to study end in YMRS total
score for all studies, excluding one 12-week study where
the primary endpoint was treatment response, defined as
≥50% improvement from baseline in YMRS total score
(Vieta et al. 2005). For the purpose of the current analysis,
data from all treated subjects were pooled and standar-
dized factor scores from principal component analysis
(as described previously (Swann et al. 2013b)) converted
to rating-scale-related scores. The factor conversion was
performed by using the subjects who comprised the fivefactor scores as the basis to calculate the mean change
from baseline to week 3 by factor score. The rating scale
values (YMRS and MADRS items) at baseline and week 3
were used to run the analyses of covariance (ANCOVA)
for mean change from baseline to week 3 by factor for
each of the treatments included in these studies, with
double-blind treatment and study as main effects, and
baseline assessment as covariate. Factor definition is pre-
sented in Table 2. All analyses were conducted using the
SAS 8.2 statistical analysis program and the last observa-
tion carried forward (LOCF).Predictive value of early efficacy
Efficacy data were also used to evaluate the ability of
early (day 4 and week 1) improvement in factor scores
to predict efficacy at endpoint (week 3), using receiver
operating characteristic (ROC) curves for percentage
change in factor score at day 4 and week 1 in predicting
factor response at week 3. Optimal percentage cut-off
scores were determined by visual inspection of the ROC
curves. Factor response was defined as a 50% improve-
ment (reduction) in factor score from baseline to week 3.
Receiver operating characteristic curves were constructed
through the use of logistics regression models for each of
the three treatment groups: aripiprazole treatment, com-
parative treatment (haloperidol and lithium combined),
and placebo.
The area under the ROC curve (AUC) represents the
percentage of randomly drawn pairs from the early im-
provement time point (day 4/week 1) and endpoint (week
3) that were correctly classified, i.e., where early efficacy
was predictive of endpoint efficacy. An AUC of 0.5 would
suggest that the test correctly classifies these subjects only
50% of the time, while an AUC of 1 would represent cor-
rect classification 100% of the time. Additionally, the ROC
curves could be used to identify the optimal percentage
change in factor score at day 4/week 1 that best predicts
response at week 3, by locating the point on the curve
nearest to the perfect classification point of 100% (0 on
the x-axis of specificity [false positive rate] and 1 on the
y-axis of sensitivity [true positive rate]).Results
Subjects
Of the 2,179 subjects included in the factor analysis, 2,174
subjects had baseline data and at least one post-baseline
efficacy evaluation for inclusion in the efficacy sample.
Subjects were assessed following treatment with aripipra-
zole (n = 1,001), haloperidol (n = 324), lithium (n = 155),
and placebo (n = 694). Treatment continuation varied from
31% to 71% at week 3 of the original studies (El Mallakh
et al. 2010; Keck et al. 2003; Keck et al. 2009; Sachs et al.
2006b; Vieta et al. 2005; Young et al. 2009).
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The effects of treatment on factor scores are shown in
Figure 1. Aripiprazole, haloperidol, and lithium signifi-
cantly improved mania factor scores compared with pla-
cebo as indicated by confidence intervals. Improvements
between baseline and week 3 in sleep disturbance, judg-
ment/impulsivity, and irritability/hostility factor scores
significantly favored aripiprazole and haloperidol treat-
ments compared with placebo, while no significant im-
provements were observed for lithium compared with
placebo (apart from factor 4). Changes in depression fac-
tor scores demonstrated the smallest treatment effect
across the treatment arms and compared with placebo.
Improvements in depression factor scores versus placebo
showed a trend for improvement for aripiprazole at week
3 (study endpoint), but the changes did not reach statis-
tical significance (Figure 2).Predictive value of early efficacy
The AUCs were >0.5 across all factors with all treat-
ments for efficacy at day 4 and week 1 as predictors of
response at week 3 (Figure 2). In general, AUCs were
greater for week 1 than for day 4. The greatest AUCs for
each treatment group observed at day 4 were factor 4
(judgment and impulsivity) for subjects treated with
aripiprazole (0.69), factor 5 (irritability/hostility) for sub-
jects receiving haloperidol and lithium (0.70), and factor
2 (mania) for placebo (0.78) (Figure 2). The greatest AUCs
for each treatment group observed at week 1 were factor
2 (mania) for subjects treated with aripiprazole or placebo
(0.80 and 0.88, respectively) and factor 4 (judgment and
impulsivity) for subjects treated with haloperidol and lith-
ium (0.80) (Figure 2). The optimal percentage improve-









































Figure 1 Effects of treatment (versus placebo) on factor scores from b
which is a pairwise comparison of active treatment versus placebo. CI, confideresponse at week 3 was generally approximately 40% to
50% across all factors and treatments (data not shown).Discussion
In the current analysis, all active treatments (aripiprazole,
haloperidol, and lithium) were significantly more effective
than placebo for the manic factor (characterized by the
classic symptoms of mania, including elevated mood and
increased motor activity). A depressed mood factor was
shown previously to be a key component of manic or
mixed episodes associated with bipolar I disorder in sub-
jects with acute manic or mixed episodes (Swann et al.
2013b). In the current analysis, which corrected for base-
line values, the effect of treatment on depressed mood
was lower than that seen with other factors. When asses-
sing the depression mood factor, aripiprazole showed an
improvement, while subjects in the haloperidol and lith-
ium groups showed worsening compared with placebo.
Although none of the changes were significant, the lack
of benefit with lithium and higher effectiveness of aripi-
prazole compared with haloperidol at lowering depressive
symptoms is in agreement with previous findings (Swann
et al. 2002; Vieta et al. 2005). Bearing in mind the low level
of depression at baseline, no meaningful clinical changes
were expected and no definitive conclusions can be drawn
from the findings presented here with regard to differen-
tial efficacy between the treatments.
Interestingly, the irritability/hostility factor - a prominent
component of manic episodes - was improved with both
aripiprazole and haloperidol compared with placebo. Lith-
ium did not demonstrate improvements in the irritability/
hostility factor in this study, raising the question of
whether irritability/hostility factor symptoms may dif-
















































































































Figure 2 Area under the ROC curve. Area under the receiver operating characteristic curve for percent change in factor score at Day 4 (a) and
week 1 (b) predicting factor response at week 3. *Confidence interval data not available. AUC, area under the receiver operating characteristic
curve; CI, confidence interval.
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irritability/hostility have been reported previously (Swann
et al. 2002).
The predictive value of response at week 3 was shown
to be nearly as good at day 4 as at week 1. Early identifi-
cation of treatment response or non-response in bipolar
disorder may be beneficial to subjects to optimize clin-
ical outcome by allowing identification of subjects that
are most likely to substantially benefit from therapy.
Similar analyses assessing benefits of early response in
subjects with bipolar depression who received aripipra-
zole showed that the absence of minimal treatment re-
sponse early during treatment predicted ultimate non-
response at study endpoint with high predictive validity
(Kemp et al. 2010; Kemp et al. 2011). This is broadly
consistent with earlier research treatment using compos-
ite mania scores which showed that response to lithium
could be predicted at day 7 (Swann et al. 1986).
It has also been shown in subjects with schizophrenia
that early treatment response encourages subjects toremain on the treatment longer with a lower rate of
treatment discontinuation (Kinon et al. 2008) potentially
leading to improved subject functioning and a reduction
in overall healthcare costs for these subjects (Ascher-
Svanum et al. 2008). Therefore, identifying patients who
may not respond to and/or remit on a chosen treatment
could be a powerful tool that enables clinicians to for-
mulate treatment regimens that shorten the exposure to
ineffective agents or refine the dose of treatments to en-
hance response. Benefits of early response on the predict-
ive value of treatment response to aripiprazole have been
documented for other indications including schizophrenia
and major depressive disorder (Correll et al. 2013; Muzina
et al. 2011).
In the current study, overlapping confidence intervals
suggest similarities in predictive power between treat-
ments; however, no formal statistical testing was per-
formed to directly compare the AUCs between treatments.
The predictive value of the placebo response (particularly
to factor 2 - mania) at both day 4 and week 1 was notably
Ostacher et al. International Journal of Bipolar Disorders  (2015) 3:11 Page 7 of 9high. This is perhaps not surprising given that most of the
studies (Keck et al. 2003; Keck et al. 2009; Sachs et al.
2006b; Young et al. 2009) included in this analysis required
inpatient hospitalization for the first 2 weeks of treatment.
Manic subjects responding to placebo at day 4 are more
likely to show a sustainable placebo response at Week 3.
Symptom improvement in response to placebo could have
been enhanced by patients potentially displaying a transi-
ent episode of mania or the structured hospital and desti-
mulated environment that may have shortened the natural
6- to 12-week duration of a manic episode (Keck et al.
2000; Vieta et al. 2005), as well as high frequency of con-
trol visits and the fixed-dose design of the treatment. Ana-
lysis of the ROC curves suggests that, in order to achieve a
clinically relevant prediction of treatment outcome at week
3, a higher percentage cut-off than the typically used 30%
was required. Therefore, the optimal early percentage
improvement in factor scores is approximately 40% to ap-
proximately 50% from baseline. However, the above obser-
vation requires further analyses on large sets of data to
establish a clinically meaningful threshold and potentially
inform new classifications and sequential treatment strat-
egies for bipolar disorder.
The Research Domain Criteria (RDoC) project (http://
nimh.nih.gov/research-priorities/rdoc/index.shtml) has
been launched by the National Institute of Mental
Health (NIMH) to aid in the development and imple-
mentation of new ways of classifying psychopathology
and grouping participants in research studies based on
dimensions of observable behavior and neurobiological
measures. The aim of the project is to create a founda-
tional research literature that informs future versions of
nosologies based upon genetics, biomarkers, and beha-
vioral neuroscience. As an initial step, a sufficient re-
search foundation is needed that can eventually inform
the best approaches for clinical diagnosis and treatment.
Factor analyses such as those presented here, while only
using principles of the RDoC, allow for a dimensional
approach to the examination of symptoms and asso-
ciated treatment outcomes that might become the basis
for comparisons of outcomes across diagnoses using
data from trials that used categorical diagnoses for study
entry. The current analysis provides an example of a
potential dimensional structure for episodes of bipolar
disorder. Factors and factor clusters developed in this
manner provide a platform for neurobiological and
treatment studies to support research into alternative
approaches for assessing psychopathology based on
more basic characteristics that may underlie symptom-
atic presentation of bipolar disorder.
Although the study above was not designed to directly
compare treatment outcome between different agents, it
may provide a promising construct for future studies to in-
vestigate the potential for symptom factors to characterizethe effects of treatment on patients with acute mania and
to assess the value of early efficacy in predicting treatment
outcome. Clinicians and patients are still using the DSM
for diagnosis, and the construct of mania is not fully ex-
plained by any domain currently in the RDoC. However,
data presented here may be relevant to provide both pa-
tients and clinicians with the tools to make a more in-
formed decision on short-term and inevitably long-term
treatment to maximize patient benefit.
Limitations
This post hoc analysis includes the pooled data of several
clinical trials. While this is a limitation, it should be noted
that the majority of the studies included (El Mallakh et al.
2010; Keck et al. 2003; Keck et al. 2009; Sachs et al. 2006b;
Young et al. 2009) used relatively similar study inclusion
criteria and thus resulted in similar subject populations
suitable for pooling. However, it should also be considered
that the inclusion criteria of the original trials may limit
the generalizability of the study findings. The 12-week
studies included in this analysis were not powered to
detect differences between active treatments at week 3.
Subject numbers for haloperidol and lithium were sub-
stantially lower than for aripiprazole and placebo and may
have limited the power for detecting relationships invol-
ving these treatments. Another limitation is the use of
LOCF data in the context of investigating symptom
change; however, regarding the short duration of these
studies and the relatively high completion rate (up to 71%
at week 3), LOCF data was deemed suitable to assess effi-
cacy at the indicated time points. The rating scale values
(YMRS and MADRS items) at baseline and week 3 were
used to run the ANCOVA for mean change from baseline
to week 3 by factor for each of the three treatments with
double-blind treatment and study as main effects and
baseline assessment as covariate. A factor conversion was
performed rather than presenting endpoint data as raw
score and adjusting for baseline response, or providing the
change in score and regressing it on treatment.
Conclusions
This post hoc analysis of data from over 2,000 subjects
with manic or mixed episodes associated with bipolar I
disorder, enrolled in six double-blind, randomized, con-
trolled clinical trials, confirmed that all active treatments
provided significant improvement compared with pla-
cebo in at least one factor (mania), with aripiprazole and
haloperidol resulting in significant efficacy in four out of
the five factors assessed. Early efficacy was found to be
predictive of efficacy at week 3 for all treatments across
all factors; however, response at week 1 was a better
early predictor than response at day 4. This analysis
confirms the value of early treatment/assessment across
a range of factors from this heterogeneous subject
Ostacher et al. International Journal of Bipolar Disorders  (2015) 3:11 Page 8 of 9population and may be useful as a means for examining
symptom dimensions in treatment trials across diagno-
ses. While exploratory, results such as these might be
part of future risk prediction models across diagnoses -
including characteristics not collected in a clinical trial
setting, potential biomarkers, and genetic markers - that
might lead to a more precise means of picking treat-
ments and predicting response for our patients.
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